Alcon, an eye care provider, is acquiring EYSUVIS pharmaceutical eye drops from Kala Pharmaceuticals.

The acquisition will complement Alcon’s portfolio in the large and fast-growing dry eye category.

“We will be pleased to add EYSUVIS to our growing pharmaceutical portfolio,” said Sergio Duplan, president, North America at Alcon. “EYSUVIS is a natural fit for our newly formed ophthalmic eye drop sales force in the United States. With our strong expertise in market access and commercial execution, we are well-positioned to build the market for acute dry eye treatment.”